SRT2104   Click here for help

GtoPdb Ligand ID: 9515

Synonyms: compound 4 [Ng et al., 2013] [5] | GSK2245840 | SRT-2104
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: SRT2104 (GSK2245840) is an investigational, selective and orally available SIRT1 activator [4-5].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 141.13
Molecular weight 516.14
XLogP 2.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1sc(nc1C)c1cccnc1)Nc1ccccc1c1cn2c(n1)scc2CN1CCOCC1
Isomeric SMILES O=C(c1sc(nc1C)c1cccnc1)Nc1ccccc1c1cn2c(n1)scc2CN1CCOCC1
InChI InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
1. Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW. (2014)
A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.
Br J Clin Pharmacol, 78 (1): 69-77. [PMID:24446723]
2. Jiang M, Zheng J, Peng Q, Hou Z, Zhang J, Mori S, Ellis JL, Vlasuk GP, Fries H, Suri V et al.. (2014)
Sirtuin 1 activator SRT2104 protects Huntington's disease mice.
Ann Clin Transl Neurol, 1 (12): 1047-52. [PMID:25574479]
3. Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J et al.. (2015)
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.
PLoS ONE, 10 (11): e0142081. [PMID:26556603]
4. Mercken EM, Mitchell SJ, Martin-Montalvo A, Minor RK, Almeida M, Gomes AP, Scheibye-Knudsen M, Palacios HH, Licata JJ, Zhang Y et al.. (2014)
SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass.
Aging Cell, 13 (5): 787-96. [PMID:24931715]
5. Ng PY, Bemis JE, Disch JS, Vu CB, Oalmann CJ, Lynch AV, Carney DP, Riera TV, Song J, Smith JJ et al.. (2013)
The Identification of the SIRT1 Activator SRT2104 as a Clinical Candidate.
Lett Drug Des Discov, 10: 793-797.
6. Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. (2016)
Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis.
Inflamm Bowel Dis, 22 (3): 607-14. [PMID:26595549]